Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent

Tina Quanbee Tan, Ram Yogev*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.

Original languageEnglish (US)
Pages (from-to)479-489
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number4
StatePublished - Jul 1 2008


  • Enterococcus
  • Gram-positive bacteria
  • Linezolid
  • Oxazolidinone
  • Staphydococcus aureus

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent'. Together they form a unique fingerprint.

Cite this